Curated News
By: NewsRamp Editorial Staff
September 25, 2025
Clene's CNM-Au8 Shows Promising Brain Energy Improvements in MS Trial
TLDR
- Clene's CNM-Au8 shows potential to slow MS progression by improving brain energy metabolism, offering a competitive edge in neurodegenerative disease treatment markets.
- CNM-Au8 works by significantly improving brain NAD+/NADH ratios and addressing bioenergetic failure through targeted mitochondrial function in both relapsing and progressive MS patients.
- This treatment improves brain energy capacity in multiple sclerosis patients, potentially enhancing quality of life by addressing the root causes of neurological disability.
- Clene's gold nanocrystal therapy demonstrates safe improvement of brain energy metabolism across MS types, revealing new pathways for neurodegenerative disease treatment.
Impact - Why it Matters
This development represents a significant advancement in multiple sclerosis treatment by targeting the underlying metabolic dysfunction rather than just immune system modulation. For the approximately 2.8 million people worldwide living with MS, CNM-Au8's mechanism of improving brain energy metabolism addresses a fundamental aspect of disease progression that current treatments don't adequately cover. The demonstrated improvements in NAD+/NADH ratios suggest potential for slowing disability progression and preserving neurological function, which could meaningfully impact patients' quality of life and long-term outcomes. As neurodegenerative diseases increasingly burden healthcare systems, therapies that address root causes rather than symptoms represent the future of neurological care.
Summary
Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on neurodegenerative diseases, announced groundbreaking results from its REPAIR-MS trial presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona. The company's investigational therapy CNM-Au8 demonstrated significant improvements in brain NAD+/NADH ratios, a crucial marker of energetic capacity, across both relapsing and non-active progressive multiple sclerosis patients. These findings are particularly noteworthy because they address the fundamental bioenergetic failure that characterizes MS progression, with treatment also producing significant changes in brain NAD+ and NADH fractions.
The clinical trial results showed compelling correlations between baseline brain energy metabolism and key clinical outcomes including disability progression, cognitive function, and motor performance. Importantly, CNM-Au8 maintained an excellent safety profile and was well tolerated by patients throughout the study period. Based in Salt Lake City, Utah with R&D operations in Maryland, Clene is pioneering first-in-class therapies that target mitochondrial function and the NAD pathway to improve central nervous system cell survival. The company's approach represents a novel therapeutic strategy that moves beyond traditional immunomodulatory treatments to address the underlying metabolic dysfunction in neurodegenerative conditions.
For investors and stakeholders following Clene's progress, the full press release detailing these promising results is available through BioMedWire, a specialized communications platform that provides comprehensive coverage of biotechnology and biomedical developments. BioMedWire serves as part of the Dynamic Brand Portfolio within the Investor Brand Network, offering extensive distribution capabilities and corporate communications solutions for companies in the life sciences sector. These positive REPAIR-MS trial outcomes reinforce CNM-Au8's potential to become a meaningful treatment option for MS patients by targeting the root cause of neuronal damage rather than just managing symptoms.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Clene's CNM-Au8 Shows Promising Brain Energy Improvements in MS Trial
